Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Active Safety Surveillance Plan to Conduct Serologic Testing for Anti-erythropoietin Antibodies and Prospectively Monitor the Incidence of Pure Red Cell Aplasia (PRCA) Among Patients Receiving Epoetin Alfa or Another Erythropoietin

NCT00210951 is registered in ClinicalTrials.gov with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. as lead sponsor.

NCT NCT00210951
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00210951 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Active Safety Surveillance Plan to Conduct Serologic Testing for Anti-erythropoietin Antibodies and Prospectively Monitor the Incidence of Pure Red Cell Aplasia (PRCA) Among Patients Receiving Epoetin Alfa or Another Erythropoietin
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase
Observational
Overall status
Completed
Start date
May 31, 2003
Completion date
July 31, 2005
Enrollment
4,761 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic renal failure, red-cell aplasia, pure